tiprankstipranks
Trending News
More News >
JBM (Healthcare) Ltd. (HK:2161)
:2161
Hong Kong Market
Advertisement

JBM (Healthcare) Ltd. (2161) AI Stock Analysis

Compare
1 Followers

Top Page

HK:2161

JBM (Healthcare) Ltd.

(2161)

Rating:81Outperform
Price Target:
HK$3.50
▲(18.24% Upside)
JBM (Healthcare) Ltd. scores well due to its strong financial performance and attractive valuation. The company's robust revenue growth and profitability, combined with a low P/E ratio and high dividend yield, make it a compelling investment. Technical indicators suggest stability, although the decline in free cash flow growth warrants monitoring.

JBM (Healthcare) Ltd. (2161) vs. iShares MSCI Hong Kong ETF (EWH)

JBM (Healthcare) Ltd. Business Overview & Revenue Model

Company DescriptionJBM (Healthcare) Ltd. is a leading provider of innovative healthcare solutions, specializing in the development and distribution of advanced medical devices, diagnostic tools, and healthcare services. The company operates primarily within the healthcare sector, focusing on enhancing patient care and improving health outcomes through its cutting-edge technology and expert services. With a commitment to quality and excellence, JBM offers a range of products including medical imaging equipment, laboratory diagnostics, and telehealth solutions.
How the Company Makes MoneyJBM (Healthcare) Ltd. generates revenue through multiple streams, primarily by selling its medical devices and diagnostic tools to hospitals, clinics, and healthcare providers. The company also monetizes its telehealth services through subscription fees and service contracts with healthcare organizations. Additionally, JBM forms strategic partnerships with other healthcare entities and technology firms, enabling collaborative projects that enhance product offerings and market reach. These partnerships often result in joint ventures or co-development agreements, further contributing to the company's earnings. The company also invests in research and development to innovate and expand its product line, which helps maintain a competitive edge and drives sales growth.

JBM (Healthcare) Ltd. Financial Statement Overview

Summary
JBM (Healthcare) Ltd. exhibits strong financial health with impressive revenue growth and profitability margins. The balance sheet is robust with low leverage, and the company is effectively generating cash relative to its net income. However, the decline in free cash flow growth is a potential risk that needs attention.
Income Statement
85
Very Positive
JBM (Healthcare) Ltd. has demonstrated strong revenue growth with an 8.57% increase in the latest year. The company maintains healthy profitability margins, with a gross profit margin of 52.88% and a net profit margin of 25.22%. The EBIT and EBITDA margins are also robust at 31.46% and 38.15%, respectively, indicating efficient operational management. Overall, the income statement reflects a solid financial performance with consistent growth and profitability.
Balance Sheet
78
Positive
The balance sheet of JBM (Healthcare) Ltd. shows a strong equity position with a debt-to-equity ratio of 0.16, indicating low leverage and financial stability. The return on equity is 18.23%, which is a positive sign of shareholder value creation. The equity ratio stands at 70.05%, reflecting a solid capital structure. However, the company should monitor its debt levels to maintain this stability.
Cash Flow
72
Positive
The cash flow statement reveals a decline in free cash flow growth by 19.05%, which could be a concern if it persists. However, the operating cash flow to net income ratio is 0.81, and the free cash flow to net income ratio is 0.91, indicating that the company generates sufficient cash to cover its net income. While cash flow management appears adequate, the negative growth trend should be addressed.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue782.29M782.29M648.41M520.32M406.14M397.16M
Gross Profit413.71M413.71M338.08M187.92M142.30M180.94M
EBITDA283.54M298.41M220.73M111.40M84.14M114.51M
Net Income197.26M197.26M130.46M57.09M24.62M22.60M
Balance Sheet
Total Assets1.55B1.55B1.39B1.40B1.33B1.38B
Cash, Cash Equivalents and Short-Term Investments205.85M205.85M140.81M152.27M69.84M94.38M
Total Debt171.75M171.75M133.41M180.10M213.09M267.92M
Total Liabilities381.16M381.16M366.75M372.10M363.30M434.25M
Stockholders Equity1.08B1.08B970.68M985.51M929.20M904.71M
Cash Flow
Free Cash Flow205.94M205.92M181.00M137.75M52.96M35.97M
Operating Cash Flow226.95M226.94M191.22M145.89M60.01M58.93M
Investing Cash Flow-75.82M-120.48M8.31M-7.05M-7.57M-24.63M
Financing Cash Flow-84.20M-41.54M-210.72M-56.04M-76.85M-13.92M

JBM (Healthcare) Ltd. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price2.96
Price Trends
50DMA
2.98
Negative
100DMA
2.61
Positive
200DMA
2.15
Positive
Market Momentum
MACD
0.02
Positive
RSI
50.17
Neutral
STOCH
27.78
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2161, the sentiment is Positive. The current price of 2.96 is above the 20-day moving average (MA) of 2.95, below the 50-day MA of 2.98, and above the 200-day MA of 2.15, indicating a neutral trend. The MACD of 0.02 indicates Positive momentum. The RSI at 50.17 is Neutral, neither overbought nor oversold. The STOCH value of 27.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2161.

JBM (Healthcare) Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
81
Outperform
HK$2.43B12.2919.22%7.11%20.65%63.21%
73
Outperform
HK$1.89B9.945.34%5.92%2.89%-68.83%
70
Outperform
HK$660.66M30.651.87%6.41%-1.99%-81.66%
68
Neutral
HK$2.79B9.6412.47%4.11%7.43%21.88%
51
Neutral
$7.84B-0.18-41.53%2.28%22.72%-1.87%
45
Neutral
HK$177.72M-33.22%-17.32%55.74%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HK:2161
JBM (Healthcare) Ltd.
2.96
2.11
248.24%
HK:1498
PuraPharm Corp. Ltd.
0.45
-0.23
-33.82%
HK:2348
Dawnrays Pharmaceutical Holdings Ltd.
1.26
0.20
18.87%
HK:2633
Jacobson Pharma Corporation Limited
1.47
0.95
182.69%
HK:3737
Zhongzhi Pharmaceutical Holdings Limited
0.78
-0.12
-13.33%

JBM (Healthcare) Ltd. Corporate Events

JBM (Healthcare) Limited Announces Successful AGM Outcomes
Jul 28, 2025

JBM (Healthcare) Limited held its Annual General Meeting on July 28, 2025, where all proposed resolutions were passed with overwhelming support. Key decisions included the approval of financial statements, the declaration of a final dividend, the re-election of directors, and the reappointment of auditors. The meeting also authorized the board to manage directors’ remuneration and granted mandates for share repurchase and issuance, reflecting strong shareholder confidence and strategic positioning for future growth.

JBM (Healthcare) Limited Updates Board of Directors Roles
Jul 28, 2025

JBM (Healthcare) Limited has announced an update to its board of directors, detailing the roles and functions of each member effective from July 28, 2025. This announcement outlines the structure of the board and its committees, which include the Audit, Remuneration, Nomination, and Executive Committees. The update may impact the company’s governance and strategic direction, potentially influencing its operations and stakeholder relations.

JBM (Healthcare) Ltd. Updates Nomination Committee Terms
Jul 28, 2025

JBM (Healthcare) Ltd. has revised the terms of reference for its Nomination Committee to enhance the process of identifying and evaluating candidates for its board of directors. This revision aims to improve board diversity and the effectiveness of the nomination process, potentially strengthening the company’s governance and stakeholder confidence.

JBM (Healthcare) Sets Record Dates for AGM and Dividend
Jul 11, 2025

JBM (Healthcare) Limited has announced the record dates for its upcoming Annual General Meeting and proposed final dividend. The company will close its register of members to determine shareholders’ eligibility to attend the meeting on July 28, 2025, and to receive the proposed final dividend on August 14, 2025. This announcement is significant for shareholders as it outlines the necessary steps to participate in the meeting and qualify for the dividend, reflecting the company’s commitment to shareholder engagement and financial distribution.

JBM (Healthcare) Limited Announces Executive Resignation and Leadership Change
Jul 8, 2025

JBM (Healthcare) Limited announced the resignation of Mr. Wong Yat Wai, Patrick as an executive director and authorized representative, effective July 8, 2025, to concentrate on business development. Mr. Wong will continue as the CEO, while Mr. Yim Chun Leung has been appointed as the new authorized representative, signaling a strategic shift in the company’s leadership structure.

JBM (Healthcare) Limited Announces Virtual AGM and Key Resolutions
Jul 3, 2025

JBM (Healthcare) Limited has announced its upcoming Annual General Meeting, which will be conducted virtually on July 28, 2025. The meeting agenda includes approving the audited financial statements, declaring a final dividend of HK11.5 cents per share, re-electing directors, and authorizing the board to fix directors’ remuneration. Additionally, shareholders will vote on resolutions to grant the board mandates to repurchase shares and issue additional shares.

JBM (Healthcare) Ltd. Announces Strategic Acquisition of Target Company
Jun 16, 2025

JBM (Healthcare) Ltd. has announced a discloseable transaction involving the acquisition of the entire issued share capital of a target company for HK$38,000,000. This acquisition, subject to certain conditions, is expected to enhance JBM’s market positioning by expanding its business operations, although it does not require shareholder approval under the Listing Rules.

JBM (Healthcare) Ltd. Reports Strong Financial Growth in 2025
Jun 12, 2025

JBM (Healthcare) Limited reported a significant financial performance for the year ended 31 March 2025, with a 20.7% increase in revenue to approximately HK$782.3 million and a 51.2% rise in profit attributable to equity shareholders to HK$197.3 million. The company also announced a substantial increase in dividends, reflecting its strong financial health and commitment to rewarding shareholders.

JBM (Healthcare) Ltd. Declares Final Dividend for FY2025
Jun 12, 2025

JBM (Healthcare) Limited has announced a final cash dividend of HKD 0.115 per share for the financial year ending 31 March 2025. The dividend will be paid on 28 August 2025, following shareholder approval on 28 July 2025. This announcement reflects the company’s financial performance and commitment to returning value to its shareholders.

JBM (Healthcare) Limited Re-designates Directors to Executive Roles
Jun 12, 2025

JBM (Healthcare) Limited has announced the re-designation of Mr. Sum Kwong Yip, Derek, and Mr. Yim Chun Leung from non-executive to executive directors, effective June 12, 2025. This move is expected to enhance the company’s strategic direction and operational management, leveraging the extensive experience of both individuals in the pharmaceutical and corporate finance fields.

JBM (Healthcare) Limited Schedules Board Meeting to Approve Final Results
May 30, 2025

JBM (Healthcare) Limited has announced a board meeting scheduled for June 12, 2025, to discuss and approve the company’s final results for the fiscal year ending March 31, 2025. The meeting will also consider the recommendation of a final dividend, highlighting potential financial implications for stakeholders.

JBM (Healthcare) Limited Expects Over 50% Profit Increase
May 19, 2025

JBM (Healthcare) Limited has announced a positive profit alert, expecting a significant increase in consolidated profit by at least 50% for the year ending March 31, 2025, compared to the previous year. This growth is attributed to strong sales performance driven by effective brand management and marketing strategies, highlighting the company’s successful positioning in the consumer healthcare market.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 30, 2025